Wedbush Research Analysts Cut Earnings Estimates for JBIO

Jade Biosciences, Inc. (NASDAQ:JBIO) – Wedbush reduced their Q3 2025 earnings per share (EPS) estimates for shares of Jade Biosciences in a note issued to investors on Thursday, August 14th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.43) per share for the quarter, down from their previous forecast of ($0.38). Wedbush currently has a “Outperform” rating and a $18.00 target price on the stock. Wedbush also issued estimates for Jade Biosciences’ Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($4.35) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.28) EPS, FY2027 earnings at ($2.46) EPS, FY2028 earnings at ($2.26) EPS and FY2029 earnings at ($2.21) EPS.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.43).

Other research analysts have also recently issued research reports about the stock. Guggenheim upgraded shares of Jade Biosciences from a “neutral” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Monday, June 16th. Wall Street Zen cut shares of Jade Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Jefferies Financial Group began coverage on shares of Jade Biosciences in a research report on Monday, July 14th. They set a “buy” rating and a $16.00 target price for the company.

Jade Biosciences Stock Up 8.7%

JBIO stock opened at $7.36 on Monday. The stock has a 50 day moving average of $8.68. Jade Biosciences has a fifty-two week low of $6.57 and a fifty-two week high of $105.00. The company has a market cap of $6.18 million, a PE ratio of -0.24 and a beta of 1.03.

Institutional Trading of Jade Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in shares of Jade Biosciences during the 2nd quarter valued at $29,000. Russell Investments Group Ltd. bought a new stake in shares of Jade Biosciences in the 2nd quarter valued at $31,000. BNP Paribas Financial Markets bought a new stake in shares of Jade Biosciences in the 2nd quarter valued at $32,000. Ameritas Investment Partners Inc. bought a new stake in shares of Jade Biosciences in the 2nd quarter valued at $33,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Jade Biosciences in the 2nd quarter valued at $71,000.

About Jade Biosciences

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.